Zhengye Biotechnology Holding Limited (ZYBT) 股票分析

公司概述

Zhengye Biotechnology Holding Limited is primarily engaged in the research, development, manufacturing, and sale of veterinary vaccines specifically designed for livestock within the Chinese market. The company's product portfolio includes vaccines for swine, cattle, goats, sheep, poultry, and dogs, covering monovalent, polyvalent, and combined formulations. Operating within the Healthcare sector as a Drug Manufacturer specializing in Specialty & Generic products, the firm focuses on biological agents essential for agricultural animal health. With a market capitalization of $45.28M and an annual revenue of $153.74M, the company employs a workforce of 277 individuals. These valuation and revenue figures indicate that Zhengye Biotechnology operates as a mid-sized entity with a significant revenue base relative to its market cap, suggesting a structure where the current stock price reflects a substantial discount to its annual earnings power or revenue scale.

财务健康

The company reported a Trailing Twelve Months (TTM) revenue of $153.74M, yet it posted a net income loss of $-19,368,000 and an EBITDA of $-2,213,000. The substantial gap between the $153.74M in revenue and the -$19.37M net income reveals a highly leveraged cost structure or significant non-operating expenses that are eroding profitability despite sales volume. Notably, the company generated positive free cash flow of $24.23M, which provides a critical buffer for financial flexibility despite the reported accounting losses. This positive cash generation suggests that the company's operational cash burn is low or that it has collected cash efficiently, allowing it to service obligations or fund operations without immediate external financing. The gross margin stands at 37.4%, indicating that the company retains a healthy portion of revenue after direct production costs, though the operating margin of -46.3% and profit margin of -12.6% demonstrate severe operational inefficiencies or high overhead costs relative to sales. On the balance sheet, the company holds $47.63M in cash against total debt of $85.76M, resulting in a debt-to-equity ratio of 23.49, which characterizes a highly leveraged financial position rather than a conservative one. The current ratio of 1.49 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting adequate short-term liquidity management. Furthermore, the Return on Equity (ROE) of -6.4% and Return on Assets (ROA) of -3.4% reveal that management is currently destroying value rather than generating returns for shareholders or efficiently utilizing the asset base.

估值评估

The trailing P/E ratio is listed as N/A due to the reported net losses, and the forward P/E is also N/A, implying that traditional earnings-based valuation multiples are currently inapplicable for assessing expected earnings trajectories. The price-to-book ratio is 1.04, which indicates that the market values the company slightly above its book value despite the negative earnings, suggesting potential undervaluation or specific asset quality considerations. Alternative valuation metrics such as the price-to-sales ratio of 0.29 and the EV/EBITDA of -67.59 provide a different perspective, highlighting that the stock trades at a fraction of its sales, while the negative EV/EBITDA reflects the firm's negative operating earnings before interest, taxes, depreciation, and amortization. The 52-week high is $14.30 and the 52-week low is $0.68, meaning the current trading price sits significantly below the annual peak and well above the annual floor, reflecting a wide trading range. The beta is listed as N/A, which means standard volatility metrics relative to the broader market cannot be calculated from the available data, limiting the ability to gauge price sensitivity to market movements using this specific coefficient.

Growth & Income

The revenue growth year-over-year stands at -34.4%, while earnings growth is N/A due to the loss position, indicating that the company is currently contracting in terms of sales volume. Since there are no earnings to compare against revenue growth, the decline in revenue suggests a contraction in market share or a drop in demand for its veterinary vaccine portfolio. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, implying that any retained earnings are reinvested into operations or used to reduce debt rather than providing income distributions. The overall growth and income profile is characterized by negative revenue expansion, significant accounting losses, and a lack of dividend income, positioning the stock purely as a speculative growth or turnaround play without current income support.